Status:
UNKNOWN
Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
Lead Sponsor:
RenJi Hospital
Conditions:
Hepatocellular Carcinoma Recurrent
Liver Transplant; Complications
Eligibility:
All Genders
18-80 years
Brief Summary
Objective of Study: This study will evaluate the heterogeneity and evolution pathway between primary HCC and tumor relapse after liver transplant. According to the "Seed-Soil" theory, the primary hyp...
Detailed Description
40 specimens will be obtained from the primary tumor during liver transplant surgery and biopsy/specimens from intrahepatic tumor or lung metastasis when the patients experience postoperative relapse....
Eligibility Criteria
Inclusion
- Patients must have pathologically or cytologically or by radiological criteria proven hepatocellular carcinoma; known mixed histology (e.g. hepatocellular carcinoma plus cholangiocarcinoma) or fibrolamellar variant is not allowed
- Patients have post-transplant HCC recurrence(cohort 1), Indication for being an candidate in the waiting list for liver transplant according to multidisciplinary board evaluation(cohort 2)
- The time frame between liver transplant and diagnosis of post-transplant HCC recurrence\> 6 months
- No prior hepatectomy or systemic therapy or local therapy (TACE etc.)
Exclusion
- History of oncological systemic treatment
- early recurrence(\<6 months)
- multiple organ transplantation
Key Trial Info
Start Date :
September 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04506398
Start Date
September 10 2020
End Date
August 1 2022
Last Update
June 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China, 200127